Moneyextra Sharedealing



ALIZYME PLC

BOARD CHANGES

Cambridge UK, 23 April 2009: Alizyme plc (LSE:AZM) announces that Sir Brian Richards has informed the Board that he intends to step down as Chairman and retire as a Director of Alizyme plc at the conclusion of the forthcoming Annual General Meeting, to be held on 24 July 2009. Sir Brian has been Chairman of Alizyme since its formation.

Mr Alan Goodman joins the Board as a Non-Executive Director with immediate effect and it is intended that he will assume the role of Chairman at the conclusion of the forthcoming Annual General Meeting.

Mr Goodman, aged 58, has founded or co-founded many biotechnology and healthcare companies over the last 25 years, including Agricultural Genetics Company, Medeva plc, Chiroscience Group plc, Acambis plc, Oxford BioMedica plc, CeNeS Pharmaceuticals plc, Core Group plc and Amura Limited. He was Chief Executive of Acambis plc, non-executive Chairman of Oxford BioMedica plc and is currently a member of the Supervisory Board of Paion AG and Chief Executive of Avlar BioVentures Limited and a director of a number of private companies. 

There are no other disclosures relating to Mr Goodman under Listing Rule LR 9.6.13. 

Tim McCarthy (Chief Executive Officer) commented:

'Sir Brian has provided invaluable guidance and advice as Chairman of Alizyme since its formation, for which I and the Company are immensely grateful. I want to thank him for his unstinting efforts and wise counsel over many years and wish him well for the future. I welcome Alan's appointment as a Non-Executive Director and believe his succession as Chairman will bring a wealth of experience to the Board and is an important step for Alizyme in pursuing its strategy to become a profitable, self-sustaining biopharmaceutical product development company.'

For further information, please contact:

Further information on Alizyme can be found on the Company's website: www.alizyme.com